scholarly journals Population-based estimates of humoral autoimmunity from the U.S. National Health and Nutrition Examination Surveys, 1960–2014

PLoS ONE ◽  
2020 ◽  
Vol 15 (1) ◽  
pp. e0226516 ◽  
Author(s):  
Charles F. Dillon ◽  
Michael H. Weisman ◽  
Frederick W. Miller
Diabetes Care ◽  
2002 ◽  
Vol 25 (8) ◽  
pp. 1326-1330 ◽  
Author(s):  
J. B. Saaddine ◽  
A. Fagot-Campagna ◽  
D. Rolka ◽  
K.M. V. Narayan ◽  
L. Geiss ◽  
...  

2019 ◽  
Vol 123 ◽  
pp. 141-147 ◽  
Author(s):  
Manori J. Silva ◽  
Lee-Yang Wong ◽  
Ella Samandar ◽  
James L. Preau ◽  
Lily T. Jia ◽  
...  

2018 ◽  
Vol 5 (suppl_1) ◽  
pp. S242-S243
Author(s):  
Hugo Lopez-Gatell ◽  
Gabriela Echaniz-Aviles ◽  
Santa Garcia-Cisneros ◽  
Miguel Angel Sánchez-Alemán ◽  
Martin Romero-Martínez ◽  
...  

Abstract Background Low vaccination rates and under-detection of cases in adolescents and young adults have been implicated in the transmission of Pertussis to children. In this study, the proportion of adolescents and young adults with anti Bordetella pertussis IgG antibodies was estimated in a population-based survey in Mexico. Methods Frozen sera and data from 1,581 subjects—1,102 adolescents and 479 young adults (10–19 and 20–25 years old, respectively)—56% female were randomly selected from the Mexico’s National Health and Nutrition Survey (ENSANUT) 2012. CDC/FDA validated PT ELISA test was used to detect anti-pertussis toxin (PT) antibodies. A subset of 300 samples was also tested with Bp-IgG PT ELISA kit (Euroimmun AG, Lubeck, Germany®), both tests used international standards. Threshold values were established to identify vaccination or infection within the previous year, according to a US survey (Baughman et al.). Population-weighted estimates of seroprevalence were calculated. Results Overall Bp seroprevalence was 3.9% (95% CI: 2.3, 6.3); 3.1% (1.9, 5.0) in adolescents, and 4.9% (2.2, 11) in young adults. Seroprevalence did not significantly vary by gender, socioeconomic status, region or rural/urban location. Compared with the CDC/FDA PT ELISA, the Euroimmun® test showed 76% sensitivity, 88% specificity. Conclusion Booster vaccination to Bp after toddlerhood is not in the Mexican national policy; therefore, anti-PT IgG seropositivity may reasonably be attributed to recent Bp infection. Our weighted estimates of recent Bp infection, which are based on a national population-based serosurvey and a standardized serological test, represent a considerable burden of infections in adolescents and young adults that sharply contrast with the official surveillance reports. Also, the Bp-IgG PT ELISA commercial kit lower sensitivity than the CDC/FDA PT ELISA may lead underestimation of recent infections. In conclusion, assessing pertussis seroprevalence requires careful consideration of the right tests and epidemiological model for interpretation. Disclosures All authors: No reported disclosures.


Sign in / Sign up

Export Citation Format

Share Document